Altimmune commences public offering to fund MASH Phase 3 trial

Altimmune, Inc. has commenced an underwritten public offering of shares of its common stock and accompanying common stock warrants (or pre-funded warrants). The company plans to use the net proceeds from this offering to fund its upcoming Phase 3 clinical trial for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), along with working capital and general corporate purposes. Leerink Partners and Barclays are acting as joint bookrunning managers for the proposed offering.